S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01309672|
Recruitment Status : Active, not recruiting
First Posted : March 7, 2011
Results First Posted : May 5, 2017
Last Update Posted : June 2, 2017
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: abiraterone acetate Drug: Prednisone||Phase 2|
- To assess the rate of achieving a prostate-specific antigen (PSA) of ≤ 0.2 ng/mL with abiraterone acetate therapy in men with metastatic prostate cancer with a sub-optimal response to androgen-deprivation therapy (ADT).
- To assess the overall survival and objective progression-free survival of this group of patients.
- To assess PSA partial response.
- To evaluate the qualitative and quantitative toxicity of abiraterone acetate.
OUTLINE: This is a multicenter study.
Patients receive abiraterone acetate orally daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients receive androgen blockade with GNRH agonist (goserelin acetate or leuprolide acetate) or a GNRH antagonist (degarelix) per the treating physician and this will be given continuously until evidence of disease progression. Bilateral surgical orchiectomy is also acceptable.
After completion of study therapy, patients are followed up every 3 months for 1 year and then every 6 months for up to 3 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||41 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II|
|Study Start Date :||August 9, 2011|
|Actual Primary Completion Date :||November 29, 2016|
|Estimated Study Completion Date :||October 2018|
Experimental: Abiraterone acetate + prednisone
Abiraterone, 1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); to be taken daily
Prednisone, 5 mg, oral, 5 mg twice daily
Drug: abiraterone acetate
1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken dailyDrug: Prednisone
5 mg, oral, 5 mg twice daily
- Number of Patients With Undetectable PSA [ Time Frame: 12 months ]undetectable PSA defined as <= 0.2 ng/mL. Patients not responding in the first year were deemed non-responders.
- Number of Patients With PSA Partial Response [ Time Frame: 12 months ]PSA reduction to < 4 ng/ml, but >0.2 ng/ml
- Objective Progression-free Survival [ Time Frame: 3 years ]Progression defined as unequivocal progression of disease, progressive disease as defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), progressive disease as defined by the Prostate Cancer Clinical Trials Working Group bone scan progression criteria, or death due to disease.
- Overall Survival [ Time Frame: 3 years ]
- Number of Patients With Toxicity of Abiraterone Acetate [ Time Frame: Up to 3 years ]Only adverse events that are possibly, probably or definitely related to study drug are reported.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01309672
Show 205 Study Locations
|Principal Investigator:||Thomas W. Flaig, MD||University of Colorado, Denver|